Cargando…

Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients

Aims: Bedaquiline is now recommended to all patients in the treatment of multidrug-resistant tuberculosis (MDR-TB) using standard dosing regimens. As the ability to measure blood drug concentrations is very limited, little is known about drug exposure and treatment outcome. Thus, this study aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Ge, Bao, Ziwei, Davies Forsman, Lina, Paues, Jakob, Werngren, Jim, Niward, Katarina, Schön, Thomas, Bruchfeld, Judith, Alffenaar, Jan-Willem, Hu, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083270/ https://www.ncbi.nlm.nih.gov/pubmed/37050904 http://dx.doi.org/10.3389/fphar.2023.1022090

Ejemplares similares

Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis
por: Zhang, Haoyue, et al.
Publicado: (2023)

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study
por: Davies Forsman, Lina, et al.
Publicado: (2018)

Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multicentre prospective cohort study in China
por: Zheng, Xubin, et al.
Publicado: (2022)

Population Pharmacokinetic Modeling of Bedaquiline among Multidrug-Resistant Pulmonary Tuberculosis Patients from China
por: Zou, Jin, et al.
Publicado: (2022)

Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP)
por: Ekqvist, David, et al.
Publicado: (2022)

A modeling‐based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study
por: Keutzer, Lina, et al.
Publicado: (2022)

Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline
por: Ding, Yangming, et al.
Publicado: (2023)

Detection of Pyrazinamide Heteroresistance in Mycobacterium tuberculosis
por: Werngren, Jim, et al.
Publicado: (2021)

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
por: Mbuagbaw, Lawrence, et al.
Publicado: (2019)

Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California
por: Katrak, Shereen, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of in vitro, in vivo methodologies and human studies
por: Alffenaar, Jan-Willem C., et al.
Publicado: (2022)

New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline
por: Leibert, Eric, et al.
Publicado: (2014)

Bedaquiline and delamanid in the treatment of multidrug‐resistant tuberculosis: Promising but challenging
por: Li, Yang, et al.
Publicado: (2018)

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline
por: Putra, Oki Nugraha, et al.
Publicado: (2021)

Bedaquiline: A Novel Diarylquinoline for Multidrug-Resistant Pulmonary Tuberculosis
por: Deshkar, Anuradha T, et al.
Publicado: (2022)

Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis
por: Wang, Xiaofeng, et al.
Publicado: (2020)

Safety and effectiveness of all-oral and injectable-containing, bedaquiline-based long treatment regimen for pre-XDR tuberculosis in Vietnam
por: Nguyen, Thi Mai Phuong, et al.
Publicado: (2022)

Bedaquiline for multidrug-resistant TB in paediatric patients
por: Moodliar, R., et al.
Publicado: (2021)

Bedaquiline: A new drug approved for treatment of multidrug-resistant tuberculosis
por: Deoghare, Shashank
Publicado: (2013)

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
por: Achar, Jay, et al.
Publicado: (2017)

Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis
por: Yao, Ge, et al.
Publicado: (2023)

Pharmacokinetic analysis of linezolid for multidrug resistant tuberculosis at a tertiary care centre in Mumbai, India
por: Resendiz-Galvan, Juan Eduardo, et al.
Publicado: (2023)

Bedaquiline versus placebo for management of multidrug-resistant tuberculosis: A systematic review
por: Singh, Surjit, et al.
Publicado: (2016)

Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis: Concern to Bedaquiline: Authors’ Reply
por: Kang, Yewon, et al.
Publicado: (2022)

Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis
por: Trevisi, Letizia, et al.
Publicado: (2023)

Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety
por: Gao, Jing-Tao, et al.
Publicado: (2021)

Correlation of drug exposure and bacterial susceptibility with treatment response for Mycobacterium avium complex lung disease: protocol for a prospective observational cohort study
por: Zheng, Xubin, et al.
Publicado: (2023)

Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis
por: Ngwalero, Precious, et al.
Publicado: (2021)

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
por: Maryandyshev, Andrey, et al.
Publicado: (2017)

Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK
por: Wolfson, Lara J., et al.
Publicado: (2015)

Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries
por: Lu, Xiaoyan, et al.
Publicado: (2017)

Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis
por: Hatami, Hossein, et al.
Publicado: (2022)

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
por: Pecora, Francesco, et al.
Publicado: (2021)

Bedaquiline (BDQ) resistance in an adolescent with multidrug-resistant tuberculosis (MDR-TB): An alarm for pediatricians
por: Cesilia, Citra, et al.
Publicado: (2023)

Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study
por: Li, Rong, et al.
Publicado: (2023)

Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill Patients
por: Märtson, Anne-Grete, et al.
Publicado: (2020)

Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Comparison of pharmacokinetics and bioavailability of bedaquiline fumarate, benzoate and maleate in dogs
por: Jaw-Tsai, S., et al.
Publicado: (2023)

Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination
por: Du, Jian, et al.
Publicado: (2021)

Barriers to Optimal Tuberculosis Treatment Services at Community Health Centers: A Qualitative Study From a High Prevalent Tuberculosis Country
por: Pradipta, Ivan S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ndtnsrf2ct7gjjsiq0401bqqok